Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091598 · ClinicalTrials.gov registry record · Phase 3
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT00091598: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00091598 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 372 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091598, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
What the finished NCT00091598 record still lists
NCT00091598 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00091598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091598 about?
NCT00091598 is a clinical study titled "ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)". The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
What is the current status of trial NCT00091598?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2004-01. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00091598?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00091598?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091598's enrollment target sits among peer trials
372 991st of 2000 higher than 1,009 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia